Yaribeygi Habib, Atkin Stephen L, Sahebkar Amirhossein
Chronic Kidney Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Weill Cornell Medicine Qatar, Doha, Qatar.
Diabetes Metab Syndr. 2019 Mar-Apr;13(2):1679-1683. doi: 10.1016/j.dsx.2019.03.031. Epub 2019 Mar 17.
Diabetes mellitus prevalence is increasing worldwide leading to increased morbidity and mortality through diabetes related microvascular and macrovascular disease. The treatment of hypertension has been shown to be a major therapeutic intervention for the prevention of cardiovascular events and other diabetes related complications in diabetes. Sodium-glucose co-transporter inhibitors (SGLT2i) are newly introduced anti-diabetes drugs that lower blood glucose by the inhibition of glucose reuptake and the induction of glycosuria. However, there is increasing evidence showing their cardiovascular benefit beyond the improvement of glycemic control. Here we review the latest findings on the effect of SGLT2i on blood pressure in diabetes.
全球糖尿病患病率正在上升，通过与糖尿病相关的微血管和大血管疾病导致发病率和死亡率增加。高血压治疗已被证明是预防糖尿病患者心血管事件和其他糖尿病相关并发症的主要治疗干预措施。钠-葡萄糖共转运体抑制剂（SGLT2i）是新引入的抗糖尿病药物，通过抑制葡萄糖重吸收和诱导糖尿来降低血糖。然而，越来越多的证据表明，它们除了改善血糖控制外，还具有心血管益处。在此，我们综述了SGLT2i对糖尿病患者血压影响的最新研究结果。
